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B lymphocytes are central players in humoral immunity. Their hyperactivity may 
result in autoimmunity and their hypoactivity leads to immunodeficiency. A variety of 
activatory and inhibitory signals modulate B cells function and the sum of these effects 
defines B cell response: survival, proliferation, anergy or apoptosis. Antigen-binding to its 
cognate B cell receptor (BCR) triggers antigen-specific humoral immune response, however 
numerous non antigen-specific stimuli influence B cells activation: Toll-like receptors (TLRs) 
recognize various pathogen-associated molecular patterns, while B cell activating factor of the 
tumor necrosis factor family (BAFF) is an endogenous soluble factor playing a role in B cell 
survival. BAFF-R, BCR and TLR9 have a prominent role in the regulation of B cells survival, 
proliferation, antibody and cytokine production [1, 2]. According to the literature, cross-talk 
between receptors can greatly affect the immune response of B lymphocytes [3, 4], therefore 
the examination of the interaction between the signaling pathways is necessary to better 
understand the fine tuning of B cell activation and the development of autoimmune diseases.  
The death receptor Fas (CD95) serves to eliminate low affinity, potentially dangerous, 
self-reactive B cells. Additional survival signals can rescue these cells from Fas-mediated cell 
death, increasing the risk of autoimmunity [5].  
Autoantibodies are highly specific markers of rheumatoid arthritis (RA). An effective 
treatment of RA is anti-CD20 (Rituximab) therapy, which depletes the peripheral B 
lymphocytes. Xencor Inc. has produced an anti-CD19 monoclonal antibody with modified Fc 
part (XmAb5871) which has ~400X higher affinity to the FcγRIIb. Through the cross-linking 
of CD19 and FcγRIIb, XmAb5871 can inhibit B cell activation without depletion [6].   
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The main goal of my thesis is to examine the signaling and functional consequences of 
the co-activation of B cells through BAFF-R, BCR and TLR9, to elucidate their rescuing 
effect on Fas-mediated apoptosis and to investigate the effect XmAb5871 on BCR- and 
TLR9-induced B cell functions. 
Aims / I. 
Effect of BAFF-R, BCR and TLR9 co-stimulation on B lymphocytes 
 
In order to gain a better insight into the activation of B cells via multiple signals, we 
investigated:  
 the cooperation between BAFF-R-, BCR- and TLR9-triggered signals in the 
phosphorylation of various signaling molecules, cell proliferation, cytokine and IgG 
production. 
 the role of TAK1 in the above mentioned functions. 
 the possible difference a) in the basal phosphorylation level of B cells from active RA 
patients and healthy donors; and b) in their responsiveness for BCR and TLR9 stimuli. 
 
Aims / II. 
Role of BAFF-R, BCR and TLR9 in the Fas mediated cell death 
 
 The death receptor family member Fas plays an essential role in the elimination of the 
low affinity, autoreactive B cells. It is well known that defective Fas signaling or excess of 
survival factors can rescue B cells from Fas mediated apoptosis, thus our objective was to 
study: 
 the survival promoting effect of BAFF-R-, BCR- and TLR9-mediated signals on the Fas-
induced cell death of A20 cells. 
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 The effect of BCR- and TLR9-mediated signals on the Fas-induced pan-caspase and 
caspase 8 activation.  
Aims / III. 
The inhibitory potential of XmAb5871 
 
Anti-CD20 is effectively used in RA treatment to eliminate autoreactive B cells, however 
it depletes the whole circulating B cell population. The anti-CD19 XmAb5871 has an 
enhanced binding capacity to the inhibitory FcγRIIb thus it can inhibit B cell functions 
without depletion. Our aim was to examine the effect of XmAb5871 on: 
 the BCR- and TLR9-induced FcγRIIb, Erk and Akt phosphorylation and the anti-Ig 
mediated Ca2+ flux. 
 B cell proliferation and on the production of IL-6, IL-10 and TNFα cytokines and total 
IgG. 




 Isolation of human peripheral and tonsillar B cells 
 Proliferation assay (CFSE) 
 Cytokine measurement assay (FlowCytomix technology) 
 Plasmablast differentiation (Flow cytometry) 
 ELISPOT (Detection of Ig-producing B cells) 
 ELISA (Measurement of Ig-secretion) 
 Flow cytometry (FCM) 
 Western Blot 
5 
 
Results and conclusions / I. 
BCR and TLR9 synergistically activates human B cells in a TAK1-dependent way 
To get a better understanding of the interplay between signaling pathways, we studied the 
effect of BAFF-R-, BCR- and TLR9-mediated signals on various B cell functions.  
 We have shown that BCR and TLR9 synergistically activate MAPKs and the NFκB 
pathway through TAK1, while AKT and FOXO1 phosphorylation is only BCR 
dependent. BAFF treatment induced IκB and p38 phosphorylation, but alone it was a 
weak activator. BCR and TLR9 co-stimulation induce synergistic B cell proliferation, 
a significant synergistic increase in IL-6, IL-10 and TNFα production and plasma cell 
generation. 
 We have proven that TAK1 plays a central role in BCR- and TLR9-induced 
synergistic B cell activation, since TAK1 inhibitor diminished the enhanced 
phosphorylation of IκB and MAPKs as well as proliferation and cytokine production 
in dual stimulated samples.  
 In context with previous results, we have verified that peripheral B cells from active 
RA patients have elevated basal activation status and we have demonstrated for the 
first time that this higher basal activation affects the responsiveness for BCR and 
TLR9 stimuli. 
 
These results revealed that BCR and TLR9 co-stimulate B cells through TAK1, while 
BAFF-R has marginal effect on B cell activation. Besides this, we have shown that 
peripheral B cells from active RA patients have decreased responsiveness for BCR and 
TLR9 ligand due to the higher basal phosphorylation status. 
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Results and conclusions / II. 
BAFF-R-, BCR- and TLR9-mediated signals rescue A20 B cells from Fas-induced 
cell death through the downregulation of caspase 8 activity 
 
Survival signals can rescue B cells from apoptosis. We have tested the effect of BAFF-R, 
BCR and TLR9 on Fas-induced cell death and caspase activation. 
 We have proven that anti-Ig, BAFF and the TLR9 ligand CpG inhibit the Fas-
mediated cell death, and the rescue effect was more pronounced in the co-stimulated 
samples. 
 Our data prove that the BCR and TLR9 rescue A20 B cells through the inhibition of 
the caspase cascade. 
 We have revealed that reduced caspase activity is due to the decreased activity of the 
initiator caspase 8 in the BCR and TLR9 ligand preincubated cells.  
 
These results provide evidence that BAFF-R-, BCR- and TLR9-mediated signals rescue B 
cells from Fas-induced cell death - at least partially - through the inactivation of the initiator 
caspase 8. In addition, there is a positive cooperation between the anti-apoptotic effect of 
BAFF, anti-Ig and CpG, suggesting their receptors can contribute to the survival of the low-







Results and conclusions / III. 
XmAb5871 inhibits human B cell activation through the co-ligation of CD19 and 
FcγRIIb 
Studying the role of XmAb5871 on anti-Ig and CpG stimulated human B cells, we obtained 
the following results: 
 We have demonstrated that the co-ligation of CD19 and FcγRIIb is sufficient to 
provoke FcγRIIb phosphorylation. 
  We have shown that BCR- and TLR9-induced AKT and ERK phosphorylation and 
also Ca2+ mobilization was diminished in XmAb5871 pretreated samples.  
 XmAb5871 also inhibits B cell proliferation, cytokine production and plasma cell 
differentiation. 
 Finally, XmAb5871 also inhibited the IgG response of RA B cells to the RA-specific 
autoantigen epitope citrullinated filaggrin peptide. 
 
We have demonstrated for the first time that XmAb5871 is capable to inhibit BCR- and also 
TLR9-induced and dual signal triggered B cell activation. It blocked B cell proliferation, 
cytokine production and plasma cell differentiation, suggesting that XmAb5871 can diminish 
B cell responses in multiple ways. Moreover, XmAb5871 inhibited the in vitro differentiation 
of citrullinated filaggrin peptide-specific antibody secreting cells from RA patients, 






In conclusion, our results suggest that BAFF-R, BCR and TLR9 can synergistically 
activate MAPKs and NFκB pathway, proliferation, cytokine production and plasma cell 
generation in a TAK1-dependent manner.  
They also promote anti-apoptotic signals through caspase 8 inactivation, thus rescue B 
cells from Fas induced apoptosis. 
 We have proven that XmAb5871 has a potential to inhibit BCR- and TLR9-
mediated B cell activation through the co-ligation of CD19 and FcγRIIb. It also 
diminished the citrullinated filaggrin peptide specific antibody production of B cells from 
RA patients. 
In conclusion, we can say that BAFF-R-, BCR- and TLR9-mediated signals 
collaborate upon the activation and in promoting survival of B cells. In addition, our data 
indicate that inhibition of TAK1 or the XmAb5871 antibody may be effective tools to 
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